Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 443-940-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From Jun. 28, 2002 to Dec. 23, 2002
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study was conducted according to EU Method B.7. OECD Guideline 407, OPPTS 870.3050 in compliance with GLP
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA: OPPTS 870.3050(Repeated dose 28-day oral toxicity study in rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: MITI: Guidelines for Screening Toxicity Testing of Chemicals
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): Reaktiv-Scharlach F01-0467
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: HARLAN WINKELMANN Gartenstr. 27, D-33178 Borchen, SPF breeding colony
- Age at study initiation: Approximately 6 wk
- Housing: Macrolon cages (type 4) on soft wood granulate in groups of 5 animals
- Diet: ssniff R/M (V1534), ad libitum, except for the period in which the animals were kept in diuresis cages
- Water: Tap water in plastic bottles, ad libitum, except for the period in which the animals were kept In diuresis cages
- Acclimation period: At least 5 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3 °C
- Humidity (%): 50±20 °C
- Photoperiod (hrs dark / hrs light): 12 h dark/12 h light
IN-LIFE DATES: From Jun. 28, 2002 to Aug. 09, 2002
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: sesame oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Test substance was suspended in the concentrations of 1.25, 5.0 and 20 % in sesame oil. After each measurement of the body weight, the calculation of the application volume was repeated. The final dosing volume was 5 mL/kg bw
VEHICLE
- Concentration in vehicle: 1.25, 5.0 and 20 % w/v
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Not applicable
- Duration of treatment / exposure:
- 29 d, 28 applications
- Frequency of treatment:
- Once a day for 28 d
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 62.5, 250, 1000
Basis:
other: Nominal in vehicle
- No. of animals per sex per dose:
- 5/sex/dose in main groups
5/sex/dose in recovery groups
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on the acute oral study results (LD50 >2000 mg/kg bw), dose levels of 0, 62.5, 250.0 and 1000.0 mg/kg bw/d were selected for the present study
- Rationale for animal assignment (if not random): Randomization using computer-generated algorithm
- Rationale for selecting satellite groups: To check the reversibility of the effects, if any
- Post-exposure recovery period in satellite groups: Yes
- Positive control:
- Not used in the study
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily in all groups
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before start of the study and once a week during the study
BODY WEIGHT: Yes
- Time schedule for examinations: before the start of the study and then twice weekly throughout the study.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes, twice a week
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE : No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period
- Anaesthetic used for blood collection: Yes (intraperitoneal injection of 67 + 6.7 mg/kg bw Ketamine HCl + Xylazine)
- Animals fasted: Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period
- Anaesthetic used for blood collection: Yes, killed by section of the vena cava cranialis in deep narcosis (intraperitoneal injection of 67 + 6.7 mg/kg bw Ketamine HCl + Xylazine) and exsanguinated
URINALYSIS: Yes
- Time schedule for collection of urine: Few days before termination of the study as well as before the end of the recovery period (overnight from Day 25 to Day 26 and from Day 39 to Day 40)
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once before start of the study and once a week during the study
- Dose groups that were examined: All groups
- Battery of functions tested: sensory reactivity, grip strength and motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals were necropsied and checked for macroscopically visible abnormalities. The autopsy included macroscopic examination of the skin, orifices, eyes, teeth, oral mucosa and internal organs.
HISTOPATHOLOGY: Yes, Following tissues/organs were preserved in a suitable fixative and processed for histopathological investigations: adrenal gland, bone marrow (sternum), brain, heart, colon, jejunum, kidneys, liver, lungs, lymph nodes (mandibular and iliac), ovaries, uterus, thyroid and parathyroid glands, prostate gland, spleen, stomach, testis, epididymides, thymus, trachea, urinary bladder, N. ischiadicus and spinal cord (cervical). - Other examinations:
- Following organs were weighed and the organ to body weight ratios calculated:
Heart, liver, kidneys, adrenal glands, spleen, testes, epididymides, ovaries, thymus and brain
- Statistics:
- t-Test for body weights and organ weights (obsolute).
Wilcoxon's Test for organ weights (relative to bodyweight), Clinical pathology data,
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No deaths occurred throughout the study. No significant treatment related clinical signs were observed. As an incidental finding one male animal of the control group had a scabby wound on the dorsal neck and another male animal of the same group had his head
inclined left, from Day 28 and 29, respectively, onwards.
BODY WEIGHT AND WEIGHT GAIN: Body weight gains were not affected by the administration of the test substance throughout the study in any groups.
FOOD CONSUMPTION AND COMPOUND INTAKE: Food consumption remained unaffected by the administration of the test substance throughout the study in all dose groups.
HAEMATOLOGY: Final and recovery hematology did not reveal any test substance related findings in any group
CLINICAL CHEMISTRY: Final and recovery clinical chemistry was considered not adversely influenced by administration of the test substance in any group
URINALYSIS: An increase in the volume of the urine in females of the intermediate and high dose group. The urine of most males of the 28-d treatment and the recovery high-dose group was discolored salmon-pink in different intensities. In female high-dose animals the urine was discolored very light to light salmon-pink in one animal of the final and three animals of the recovery group.
NEUROBEHAVIOUR: Neurotoxicological measurements including 'open field' observations, assessment, of sensory function, and forelimb and hindlimb grip strength were not influenced by the administration of the test substance in all groups.
ORGAN WEIGHTS: Mean absolute and relative organ weights were not affected by administration of the test substance in any group.
GROSS PATHOLOGY: Discoloured organs (kidneys, testes, adipose tissue, spleen, and/or gastrointestinal tract) in all high dose males and in three high dose female animals at the terminal necropsy. Additionally, discoloured testes were seen in high dose males after the recovery period. There was one mid dose female with red discoloured spleen.
HISTOPATHOLOGY: NON-NEOPLASTIC: There were no histopathological findings that could be related to administration of the test substance.
HISTORICAL CONTROL DATA (if applicable): Most changes were within the historical control data range
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant biological effects were observed at any dose levels
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
None
Applicant's summary and conclusion
- Conclusions:
- Under the test conditions, the NOAEL of the test substance was determined to be 1000 mg/kg bw/day in SD rats
- Executive summary:
A study was conducted to assess the sub acute repeated dose toxicity of the test substance in rats according EU Method B.7, OECD guideline 407, OPPTS 870.3050 and MITI Guidelines for screening toxicity testing of chemicals in compliance with GLP
Groups of male and female rats received test substance by oral gavage at dose levels of 0, 62.5, 250 or 1000 mg/kg bw/day for a period of 28 d. On Day 29, 5 males and five females from each group were killed and necropsied. Five males and five females from the control and high dose group were killed and necropsied after a recovery period of 14 d.
Behavior and state of health were observed daily in all groups, Body weights and food consumption were recorded twice weekly. Once before the first treatment and once a week thereafter detailed clinical observations were performed in all animals outside the home cage in a standard arena ('open field'). Additionally, the animals were examined for opacity of the refracting media of the eyes and damage to the oral mucosa.
Neurotoxicological measurements including assessment of sensory function, motor activity, forelimb and hind limb grip strength were conducted at the end of the treatment period. Hematological examinations, clinical chemistry and urine analysis were carried out at the end of the treatment period and after the recovery period.
During necropsy the animals were examined for macroscopically visible abnormalities, the main organs were weighed and the organ to body weight ratios calculated. Organs and tissues were processed for histopathological examination and checked for microscopically visible changes.
Body weights, hematological and clinical chemistry data, urine data (volume, specific weight), absolute and relative organ weights and neurotoxicological measurements (motor activity, forelimb and hind limb grip strength) were analysed with the aid of a statistical program.
No deaths occurred throughout the study. Body weight development, food consumption and general health status including Neurobehaviour were not affected by the administration of the test substance throughout the study in any groups.
Clinical pathology (hematology, clinical chemistry, and urinalysis) was not adversely affected by administration of the test substance in any group.
Organ weights were not affected by administration of the test substance in any group, and no compound-related changes were detected at necropsy or histopathology.
In conclusion, repeated administration of test substance did not cause any substance related changes at the doses administered. Hence, under the test conditions, NOAEL of the test substance was determined to be 1000 mg/kg bw/day in SD rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Aunque la ECHA ofrece una gran cantidad de material en su idioma, una parte de esta página está solo disponible en inglés. Más información sobre la política de multilingüismo de la ECHA.
Bienvenido a la página web de la ECHA. Este sitio no es plenamente compatible con Explorer 7 (y versiones anteriores). Por favor, actualice su Internet Explorer a una versión más reciente.
Esta web utiliza cookies para mejorar su experiencia de navegación en nuestros sitios web.
Más información sobre el uso de cookies.